Nonetheless, 15–20% of patients (pts) with BCR-ABL+ ALL or CML-BC develop CNS relapse during ongoing imatinib therapy [1]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.